ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on November 22, 2024. The report addresses a regulatory compliance matter regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory status rather than financial performance.
Material Changes
- Nasdaq Compliance: On November 21, 2024, the Company received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement (Listing Rule 5550(a)(2)).
- Public Announcement: A press release announcing this regained compliance was issued on November 22, 2024.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or new risk factors. The primary contingency addressed was the risk of delisting due to non-compliance with the minimum bid price, which has now been resolved.
Investor Verification Checklist
- Verify the current trading price of NDRA on Nasdaq to confirm sustained compliance with the minimum bid price requirement.
- Review the press release (Exhibit 99.1) for any additional details on the company's capital structure or stock split history that may have influenced the bid price.
- Confirm the company's ongoing compliance with other Nasdaq listing standards beyond the minimum bid price.